I-Melanoma Skin Skin and Young

Cinga iMelanoma Echaphazela Abantu Abadala? Cinga kwakhona!

I-Melanoma , uhlobo olunefuthe kakhulu lomdlavuza wesikhumba, lunokubandezela abantu babo bonke ubudala, ukususela kumncinci ukuya kumdala kunye nabo bonke abaphakathi. Ukubonelela ngengqiqo yeengcungcipheko ezibhekiselele kwindlala ye-melanoma kunye nendlela abantu abatsha abachaphazelekayo ngayo, saphendukela kuRobert A. Weiss, MD.

UDkt. Weiss ungumongameli we-American Society yeDermatologic Surgery (ASDS), inhlangano engenzi-nzuzo engama-5 000 emele i-dermasurgeons, oogqirha abaqinisekisiweyo bebhodi abaqeqeshwe ngokukodwa ukuba baphathe impilo, umsebenzi kunye nokubonakala kwesikhumba kunye nezicubu ezithambileyo.

Ziqhele kangakanani i-melanoma kubantu abaselula?

I-Melanoma yindlela efile kakhulu yomdlavuza wesikhumba kwaye ngowona wesibini umdla oqhelekileyo kubasetyhini abaneminyaka engama-20 ukuya ku-29. Ukuba ingabanjwanga kwisigaba sawo sokuqala, i-melanoma inokusasazeka kwezinye iindawo zomzimba. I-Melanoma itholakala naphi na emzimbeni, zombini kwiindawo ezibonakalayo zelanga kunye neendawo ezikhuselekileyo zesikhumba. Yibangelwa ukushisa ilanga kwaye ingaba nemfuza .

Ukuba umntu oneminyaka engaphantsi kwe-30 ubudala unobumba obumnyama, kwaye kulula, ngaba ngokwenene kufuneka bakhathazeke nge-melanoma?

Nangona abantu abadala bekhulile ukuba babe nomngcipheko ophezulu wokuphucula umdlavuza wesikhumba, iziganeko zomhlaza wesikhumba zikhuphuka ngokukhawuleza kubantu abadala abaneminyaka engama-20 ukuya ku-29. Iingcali zibonisa ukuba oku kukhangela ngokugqithiseleyo kunye nokusetyenziswa kweebhedi zokuqhawula .

Uphando olutsha lwe-genetic oluvela kwi-American Association for Research Cancer lubonisa ukuba abantu abanomfutho obumnyama abanokutshisa ilanga ngokulula banokuba besengozini yokuba nomhlaza wesikhumba unokufa.

Uphando lubonisa ukuba nabantu abangazange balunyiswe kakubi ngelilanga basenokuba besengozini enkulu ye-melanoma.

Ngaba ukuthungulwa kwee-salon kuyiyona nto ingakhuselekanga? Abanye bathi banika i-Vitamin D efuna umzimba wethu.

Kukho ukungaqondi kakuhle ukuba imibhede yokucoca ikhuselekile. Uluntu kufuneka luqaphele ingozi ye-UV radiation kwaye uqonde ukuba ngenxa yokuba ungaboni umonakalo ngokukhawuleza, akuthethi ukuba akukho.

Enyanisweni, uphando olutshanje lubonisa ukuba kukho ingozi engama-75 ephezulu ye-melanoma kubantu abaqala ukusebenzisa imibhede yokuqhawula ngaphambi kokuba baneminyaka engama-35. Ukongeza, iibhedi zokuqhawula zikhawuleza ukuguga kwesikhumba.

Uphando lubonisa ukuba ulwaphulo lwe-Vitamin D ngexesha lobuncinci ludibaniswa nokuphuhliswa kwexesha lomva, umphunga, kunye ne-prostate cancer, kwaye uncomela umthombo ongcono kakhulu weVithamini D iyimizuzu eyi-10 ukuya kwe-15 yokukhanya kwelanga. Ngelishwa, le ngcebiso ingabangela ingozi ngakumbi kunokuba yinto enhle.

Kukho iindlela ezingcono eziza kunika umzimba umzimba ofunekayo wemihla ngemihla ye-Vitamin D:

  1. Khetha ukutya okuphezulu kwi-Vitamin D njengenxalenye yokutya kwansuku zonke. Inokufumaneka kwizinto ezifana namaqanda, ijusi le-orange, ubisi, i-cereal, kunye nentlanzi. Ukongeza, ukutya okuyi-Vitamin D-eneenqwelomoya kuya kubhalwe ngokucacileyo kwaye kunikeze abathengi ngeendlela ezahlukeneyo.
  2. Izithako ze-Vitamin D: Iindidi ezininzi ze-vitamin supplement zifumaneka ngaphandle kwemithi. Into ebaluleke kakhulu yokuthatha izongezo kukuba umzimba awudingi ukuguqula i-vitamin ukuze isebenzise, ​​njengoko ihambelana nemisindo ye-UV yelanga. Izibonelelo zindlela elula kwaye elula yokufumana i-Vitamin D emzimbeni.
  3. Ukukhanya kwelanga kwansuku zonke: Kuthatha nje imizuzu embalwa yokukhanya kwelanga, njengokuhamba ukusuka emotweni ukuya kwivenkile, ukuze umzimba uvelise iVithamini D. Akukho mfuneko yokufuna ukukhanya kwelanga elongezelelweyo kunye nomngcipheko wokuba nomdlavuza wesikhumba.

Kutheni kubalulekile ukufumanisa umdlavuza wesikhumba kusasa?

Inqanaba leminyaka emihlanu yokusindisa abantu abane-melanoma ifunyanwa kwaye iphathwa phambi kokuba isasazeka iphantse i-100 ekhulwini. Ngoko ke, kubalulekile ukwenza uvavanyo lwesikhumba rhoqo. Zombili i- basal cell kunye ne- squamous cell carcinoma nazo zincono ngaphezu kwama-95 ekhulwini kwi-five-year survival rate xa zifunyenwe kwaye ziphathwa ngokukhawuleza.

Yiziphi iingcebiso ozifumanayo kubantu abatsha abajongene noontanga kunye noxinzelelo lwezenhlalakahle ukuba banqunywe okanye bangayinaki ukuphepha kwelanga?

Ndingathanda ukugxininisa iingozi zokushuca kunye nokungabikho kokuphepha kwelanga. Abantu abaselula kufuneka baqonde ukuba omnye waseMerika uyafa nge-melanoma malunga neyure nganye.

Ukuba baya kuphuma ilanga, bafanele bathathe amanyathelo okuzikhusela ukuze bavikele emisebeni yelanga elonakalisayo.

Abantu abaselula kufuneka balandele amathiphu amanyathelo okukhusela ilanga ukuqinisekisa ukukhutshwa kwesikhumba:

I-American Society yeDermatologic Surgery ibonisa njani umngcipheko we-melanoma kubantu abatsha?

Umkhankaso wethu othi "phantse i-100%" kwi-Facebook.com ubonisa umyalezo obalulekileyo ukuba umdlavuza wesikhumba uphelelwa ngama-100 ekhulwini xa unyango lomhlaza wesikhumba unyaka wenziwa ngumgqirha we-dermatologic kwaye umhlaza ubanjwe kwifom yokuqala. I-ASDS inqume ukudala iphepha le-Facebook ukuze lifike kubantu abancinci kwaye libonelele ngezixhobo ezinokusindisa ubomi babo. Isayithi iboniswe ukuba ivumele ukuba abalandeli batshintshele amabali, bathumele iifoto baze bagcine ingxoxo evulekileyo ngomhlaza wesikhumba.

I-ASDS 'I-Skin Self-Exam Kit ingakhululwa ngaphandle kwephepha elingaphantsi kwe-100%, kunye ne-website ye-ASDS, www.asds.net. Ikiti iquka imiyalelo malunga nokubeka iliso ngokufanelekileyo kunye nokulinganisa i-moles kunye nezinye izilonda, inika iinkcukacha kunye nemvelaphi malunga nomhlaza wesikhumba, kunye nemimiselo yento ekufuneka uyijonge xa ​​ubeka iliso kwi-moles kunye ne-freckles ye- ABCDE ye-melanoma :

Ukongeza, i-ASDS inikeze abathengi ngephepha leenyanga ezili-12, elibandakanya umzobo womzimba ukubanceda ukulandelela indawo ye-mole kunye nokutshintsha kwesikhumba.

Umthombo:

URobert A. Weiss, MD. I-intanethi. 15 Meyi 2009.